header logo image


Page 6«..5678..20..»

Archive for the ‘Neuropathy’ Category

Diabetic Peripheral Neuropathy Treatment Industry Market Market Go Advanced and Next Generation South Florida Theater Review – South Florida Theater…

Wednesday, March 3rd, 2021

The research report focuses on target groups of customers to help players to effectively market their products and achieve strong sales in the global Diabetic Peripheral Neuropathy Treatment Industry Market Market. It segregates useful and relevant market information as per the business needs of players. Readers are provided with validated and revalidated market forecast figures such as CAGR, Diabetic Peripheral Neuropathy Treatment Industry Market market revenue, production, consumption, and market share. Our accurate market data equips players to plan powerful strategies ahead of time. The Diabetic Peripheral Neuropathy Treatment Industry Market report offers deep geographical analysis where key regional and country level markets are brought to light. The vendor landscape is also analysed in depth to reveal current and future market challenges and Diabetic Peripheral Neuropathy Treatment Industry Market business tactics adopted by leading companies to tackle them.

Market dynamics including drivers, restraints, Diabetic Peripheral Neuropathy Treatment Industry Market market challenges, opportunities, influence factors, and trends are especially focused upon to give a clear understanding of the global Diabetic Peripheral Neuropathy Treatment Industry Market market. The research study includes segmental analysis where important type, application, and regional segments are studied in quite some detail. It also includes Diabetic Peripheral Neuropathy Treatment Industry Market market channel, distributor, and customer analysis, manufacturing cost analysis, company profiles, market analysis by application, production, revenue, and price trend analysis by type, production and consumption analysis by region, and various other market studies. Our researchers have used top-of-the-line primary and secondary research techniques to prepare the Diabetic Peripheral Neuropathy Treatment Industry Market report.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=3027073&source=atm

Our impartial and unbiased approach toward Diabetic Peripheral Neuropathy Treatment Industry Market market research is one of the major benefits offered with this research study. While internal analysis holds great importance in market research, secondary research helps guide changes during the preparation of a Diabetic Peripheral Neuropathy Treatment Industry Market research report. We dont simply take the word of third parties, we always look for justification and validation before using their data or information in our research study. We have attempted to give a holistic view of the global Diabetic Peripheral Neuropathy Treatment Industry Market market and benchmark almost all important players of the industry, not just the prominent ones. As we focus on the realities of the global Diabetic Peripheral Neuropathy Treatment Industry Market market, be rest assured that you are on the right path to receiving the right information and accurate data.

In Chapter 4 and 14.1,on the basis of types, the Diabetic Peripheral Neuropathy Treatment market from 2015 to 2025 is primarily split into:AntimunocelASP-8477BNV-222CapsaicinCBX-129801Others

In Chapter 5 and 14.2, on the basis of applications, the Diabetic Peripheral Neuropathy Treatment market from 2015 to 2025 covers:HospitalClinicOthers

Competitive Landscape

Key players of the global Diabetic Peripheral Neuropathy Treatment Industry Market market are profiled on the basis of various factors, which include recent developments, business strategies, financial strength, weaknesses, and main business. The Diabetic Peripheral Neuropathy Treatment Industry Market report offers a special assessment of top strategic moves of leading players such as merger and acquisition, collaboration, new product launch, and partnership.

Companies Includes

Request Discount on this Report @ https://www.researchmoz.com/enquiry.php?type=D&repid=3027073&source=atm

Our objective data will help you to make informed decisions related to your business. The powerful insights provided in the Diabetic Peripheral Neuropathy Treatment Industry Market report will lead to better decision-making and deliverance of actionable ideas. The information that this research study offers will assist your business to the position in the best manner possible for driving Diabetic Peripheral Neuropathy Treatment Industry Market market growth and gain sound understanding about issues affecting the industry and the competitive landscape. Players can actually improve their reputation and standing in the global Diabetic Peripheral Neuropathy Treatment Industry Market market as they develop improved business strategies and gain more confidence with the help of the research study.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=3027073&licType=S&source=atm

Table of Contents

Market Overview: In this section, the authors of the report provide an overview of products offered in the global Diabetic Peripheral Neuropathy Treatment Industry Market market, market scope, consumption comparison by application, production growth rate comparison by type, highlights of geographical analysis in Diabetic Peripheral Neuropathy Treatment Industry Market market, and a glimpse of market sizing forecast.

Manufacturing Cost Analysis: It includes manufacturing cost structure analysis, key raw material analysis, Diabetic Peripheral Neuropathy Treatment Industry Market industrial chain analysis, and manufacturing process analysis.

Company Profiling: Here, the analysts have profiled leading players of the global Diabetic Peripheral Neuropathy Treatment Industry Market market on the basis of different factors such as markets served, market share, gross margin, price, production, and revenue.

Analysis by Application: The Diabetic Peripheral Neuropathy Treatment Industry Market report sheds light on the consumption growth rate and consumption market share of all of the applications studied.

Diabetic Peripheral Neuropathy Treatment Industry Market Consumption by Region: Consumption of all regional markets studied in the Diabetic Peripheral Neuropathy Treatment Industry Market report is analysed here. The review period considered is 2014-2019.

Diabetic Peripheral Neuropathy Treatment Industry Market Production by Region: It includes gross margin, production, price, production growth rate, and revenue of all regional markets between 2014 and 2019.

Competition by Manufacturer: It includes production share, revenue share, and average price by manufacturers. Diabetic Peripheral Neuropathy Treatment Industry Market market analysts have also discussed the products, areas served, and production sites of manufacturers and current as well as future competitive situations and trends.

Contact Us:

ResearchMoz

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Read the original:
Diabetic Peripheral Neuropathy Treatment Industry Market Market Go Advanced and Next Generation South Florida Theater Review - South Florida Theater...

Read More...

Diabetic Neuropathy Market Outlook, Strategies, Manufacturers, Countries, Type and Application, Global Forecast To 2026 – Technology Magazine

Wednesday, March 3rd, 2021

Market Study Report, LLC, has recently added a report on ' Diabetic Neuropathy market' which offers a comprehensive synopsis of revolving market valuation, market size, SWOT analysis, revenue estimation and geographical spectrum of the market. The report further elucidates primary business obstacles and growth prospects within the forecasted timeline, while examining the current competitive sphere involving key players of the ' Diabetic Neuropathy market'.

The research analysis of Diabetic Neuropathy market provides a broad perspective of the major development trends, limitations, and restraints as well as growth opportunities, which are slated to define the industry growth rate in the subsequent years.

Request a sample Report of Diabetic Neuropathy Market at:https://www.marketstudyreport.com/request-a-sample/3171246?utm_source=technologymagazine.org&utm_medium=Ram

According to the report, the Diabetic Neuropathy market is predicted to witness a y-o-y growth rate during the analysis timeframe (2021-2026) and generate lucrative returns by the end of the forecast duration.

The advent of COVID-19 pandemic is expected to have some modifications to the growth of this business vertical. Various organizations operating in this industry landscape are compelled to revisit their respective budgets in order to establish a proper profit trajectory for the ensuing years. Thus, the study offers an in-depth analysis regarding the impact of the COVID-19 pandemic on the overall industry remuneration.

Apart from this, the document also highlights the various segmentations and their individual contribution towards the overall market outlook.

Major information from the Diabetic Neuropathy market report:

Ask for Discount on Diabetic Neuropathy Market Report at:https://www.marketstudyreport.com/check-for-discount/3171246?utm_source=technologymagazine.org&utm_medium=Ram

Diabetic Neuropathy Market segments covered in the report:

Regional segmentation: North America, Europe, Asia-Pacific, South America, Middle East and Africa

Product types:

Applications spectrum:

Competitive outlook:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-diabetic-neuropathy-market-2021-by-company-regions-type-and-application-forecast-to-2026

Key Highlights Questions?

Table of Content:

Read More Reports On: https://www.marketwatch.com/press-release/monodose-packaging-for-probiotics-and-nutraceutical-market-share-growth-statistics-by-application-production-revenue-forecast-to-2026-2021-02-05

Read More Reports On: https://www.marketwatch.com/press-release/automotive-biometrics-market-size-overview-growth-factors-demand-trends-and-forecast-to-2027-2021-03-01

Contact Us:Corporate Sales,Market Study Report LLCPhone:1-302-273-0910Toll Free:1-866-764-2150Email:[emailprotected]

Visit link:
Diabetic Neuropathy Market Outlook, Strategies, Manufacturers, Countries, Type and Application, Global Forecast To 2026 - Technology Magazine

Read More...

Neuropathy Pain Treatment Market In-Depth Analysis, Growth Strategies and Comprehensive Forecast to 2029 KSU | The Sentinel Newspaper – KSU | The…

Wednesday, March 3rd, 2021

Neuropathy Pain Treatment Market Forecast (2020-2029):

The most recent exploration report on the worldwide Neuropathy Pain Treatment market covers late patterns found in the overall market. This study rotates around the latest events, for example, the mechanical enhancements, item improvements, and their results in the worldwide Neuropathy Pain Treatment market. The industry contains data gathered from different fundamental and helper sources. This information has been approved by business specialists and experts, accordingly giving gigantic pieces of information to the partners, inspectors, administrators, and industry pioneers.

The Neuropathy Pain Treatment Market report also covers a detailed comprehension of the major geographies present in the market along with the key segments and sub-segments. The report focuses on regional development status, which includes the market size, share, and volume. Additionally, this report covers the manufacturers data, including business distribution, cost and price, margin, and gross revenue. This allows a reader to understand consumers behaviour and a better understanding of the leading competitors operation in the market.

Key players in the market include Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals

Major Types includes

Calcium Channel Alpha 2-Delta Ligands

Serotonin-Norepinephrine Reuptake Inhibitors

Others

Major Applications includes

Retail Pharmacies

Hospitals

Others

The Neuropathy Pain Treatment Industry research reveals insight into a top to bottom investigation of the subjective and quantitative perspectives by various industry experts and key assessment pioneers, to introduce a nitty-gritty examination into the Neuropathy Pain Treatment market and industry standards. Further, the report gives a thorough knowledge of the recorded and present market scene, incorporating future gauge concerning the specialized headways, request and supply investigation, miniature and full-scale efficient variables, administering elements, and improvement designs on the lookout. The report reveals insight into the key procedures embraced by the main parts on the lookout.

Avail a Sample copy of This Report @ https://www.regalintelligence.com/request-sample/159875

Key Target Audience:

Additional Information:

This report provides:

Avail Discount on This Report @ https://www.regalintelligence.com/check-discount/159875

Follow Us:LinkedIn: https://in.linkedin.com/company/regal-intelligenceFacebook: https://www.facebook.com/regalintelligenceTwitter: https://twitter.com/RI_insights

Read this article:
Neuropathy Pain Treatment Market In-Depth Analysis, Growth Strategies and Comprehensive Forecast to 2029 KSU | The Sentinel Newspaper - KSU | The...

Read More...

Global Neuropathy Pain Treatment Market 2021 by Company Regions Type and Application Forecast to 2027 : Pfizer, Endo, Depomed, Eli Lilly, Arbor…

Wednesday, March 3rd, 2021

The research report on global Neuropathy Pain Treatment market by OrbisPharmaReports comprises of the study of all the dynamics associated with the market. The comprehensive analysis of potential customer base, market values and future scope is included in the global Neuropathy Pain Treatment market report. Along with that the research report on the global market by OrbisPharmaReports holds all the vital information regarding the latest technologies and trends being adopted or followed by the vendors across the globe.

Get Sample Copy Of Report Here: https://www.orbispharmareports.com/sample-request/104355

The up-to-date information of the factors like profitability, product knowledge, revenue, industry growth, end users, etc. included in the research report provide great help to vendors in the industry to expand the boundaries of their businesses in the market. The research report covers all the necessary data regarding the market patterns of the growth in the market and the factors providing momentum to this growth. The research report by OrbisPharmaReports offers detailed study of an important microscopic view of the industry to define manufacturers footprints by awareness of manufacturers worldwide sales and costs, and manufacturers production over the forecast era. Leading and dominant players in the global Neuropathy Pain Treatment market are intrinsically analyzed on the basis of key factors in the competition analysis portion of the study. The study includes a detailed overview and reliable athlete sales estimates for the forecasted timeframe.

Neuropathy Pain Treatment Market Top Manufactures Details Here:

Pfizer, Endo, Depomed, Eli Lilly, Arbor Pharmaceuticals, Grnenthal Group, etc.

Browse the Complete Here: https://www.orbispharmareports.com/global-neuropathy-pain-treatment-market-2020-by-company-regions-type-and-application-forecast-to-2025/

The report by OrbisPharmaReports also covers the current market size and volume with an accurate and reliable numerical data. This helps vendors and manufacturers across the globe to understand the ups and downs in the Neuropathy Pain Treatment industry. The research report by OrbisPharmaReports also covers the detailed analysis of all the latest trends and technologies being introduced in the market. This analysis helps vendors to cope up with the intense competition in the industry on global level. An in-depth comparative and thorough analysis of the global Neuropathy Pain Treatment market offered in the research report by OrbisPharmaReports on the global Neuropathy Pain Treatment market. Furthermore, the report offers the deep analysis of the risks and opportunities offered in the market.

By the product type, the market is primarily split into

Calcium Channel Alpha 2-delta Ligands, Serotonin-norepinephrine Reuptake Inhibitors, Others, etc.

By the application, this report covers the following segments

Neuropathy Pain Treatment has been segmented into Retail Pharmacies, Hospitals, Others, etc.

The research report also covers the study of another major market aspect which is the regional study. The research report on the global Neuropathy Pain Treatment market by OrbisPharmaReports includes an insightful data on the size and volume of each region in market terms. The report gives the numerical data stating the share in the market per region. Some of these regions are Asia Pacific, Africa, North America, Middle East, Europe, South America, etc. The research report also holds crucial information regarding the segments of the global Neuropathy Pain Treatment market. The segments included in the report by OrbisPharmaReports are types, region, application, etc. The research report offers the study of major investments, operational business decisions, collaborations, mergers, etc. in the industry over the recent years.

For Any Query on the Report: https://www.orbispharmareports.com/enquiry-before-buying/104355

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

More:
Global Neuropathy Pain Treatment Market 2021 by Company Regions Type and Application Forecast to 2027 : Pfizer, Endo, Depomed, Eli Lilly, Arbor...

Read More...

Neuropathy Pain Treatment Market is Thriving Worldwide with Pfizer, Depomed, Eli Lilly, Endo The Bisouv Network – The Bisouv Network

Wednesday, March 3rd, 2021

The Latest Released Neuropathy Pain Treatment market study has evaluated thefuture growth potential of Neuropathy Pain Treatment marketand provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Neuropathy Pain Treatment market. The study includes market share analysis and profiles of players such as Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals.

If you are a Neuropathy Pain Treatment manufacturer and would like to check or understand policy and regulatory proposal, designing clear explanations of the stakes, potential winners and losers, and options for improvement then this article will help you understand the pattern with Impacting Trends.Click To get SAMPLE PDF (Including Full TOC, Table & Figures)

Major Highlights of the Neuropathy Pain Treatment Market report released by HTF MI

Market Breakdown by Applications: Retail Pharmacies, Hospitals & Others

Market Breakdown by Types: , Calcium Channel Alpha 2-delta Ligands, Serotonin-norepinephrine Reuptake Inhibitors & Others

Revenue and Sales Estimation Historical Revenue and sales volume is presented and further data is triangulated with top-down and bottom-up approaches to forecast complete market size and to estimate forecast numbers for key regions covered in the report along with classified and well recognized Types and end-use industry.

SWOT Analysis on Neuropathy Pain Treatment PlayersIn additional Market Share analysis of players, in-depth profiling, product/service and business overview, the study also concentrates on BCG matrix, heat map analysis, FPNV positioning along with SWOT analysis to better correlate market competitiveness.

Demand from top notch companies and government agencies is expected to rise as they seek more information on COVID-19. Check Demand Determinants section for more information.

Regulation Analysis Local System and Other Regulation: Regional variations in Laws for the use of Neuropathy Pain Treatment Regulation and its Implications Other Compliances

Have Any Query? Ask Our Expert @:https://www.htfmarketreport.com/enquiry-before-buy/3088088-neuropathy-pain-treatment-market-1

FIVE FORCES & PESTLE ANALYSIS:

In order to better understand Market condition five forces analysis is conducted that includes Bargaining power of buyers, Bargaining power of suppliers, Threat of new entrants, Threat of substitutes, Threat of rivalry.

Political (Political policy and stability as well as trade, fiscal and taxation policies) Economical (Interest rates, employment or unemployment rates, raw material costs and foreign exchange rates) Social (Changing family demographics, education levels, cultural trends, attitude changes and changes in lifestyles) Technological (Changes in digital or mobile technology, automation, research and development) Legal (Employment legislation, consumer law, health and safety, international as well as trade regulation and restrictions) Environmental (Climate, recycling procedures, carbon footprint, waste disposal and sustainability)

Book Latest Edition of Study Neuropathy Pain Treatment Market With COVID-19 Impact Analysis @https://www.htfmarketreport.com/buy-now?format=1&report=3088088

Heat map Analysis, 3-Year Financial and Detailed Company Profiles of Key & Emerging Players:

Geographically, the following regions together with the listed national/local markets are fully investigated: APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) North America (U.S., Canada, and Mexico) South America (Brazil, Chile, Argentina, Rest of South America) MEA (Saudi Arabia, UAE, South Africa)

Some Extracts from Neuropathy Pain Treatment Market Study Table of Content

Neuropathy Pain Treatment Market Size (Sales) Market Share by Type (Product Category) [, Calcium Channel Alpha 2-delta Ligands, Serotonin-norepinephrine Reuptake Inhibitors & Others] in 2020Neuropathy Pain Treatment Market by Application/End Users [Retail Pharmacies, Hospitals & Others]Global Neuropathy Pain Treatment Sales and Growth Rate (2015-2025)Neuropathy Pain Treatment Competition by Players/Suppliers, Region, Type and ApplicationNeuropathy Pain Treatment (Volume, Value and Sales Price) table defined for each geographic region defined.Supply Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis..and view more in complete table of Contents

Check it Out Complete Details os Report @https://www.htfmarketreport.com/reports/3088088-neuropathy-pain-treatment-market-1

Thanks for reading this article; HTF MI also offers Custom Research services providing focused, comprehensive and tailored research according to clientele objectives. Thanks for reading this article; you can also get individual chapter wise section or region wise report like Balkan, China based, North America, Europe or Southeast Asia.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us atLinkedIn|Facebook|Twitter

Read this article:
Neuropathy Pain Treatment Market is Thriving Worldwide with Pfizer, Depomed, Eli Lilly, Endo The Bisouv Network - The Bisouv Network

Read More...

Diabetic Neuropathy Drugs Market Key Drivers, Applications, Challenges and Opportunities, 2021-2028 – The Courier

Wednesday, March 3rd, 2021

This report is presented in a clear and concise way to help you better understand market structure and dynamics. Recent trends and developments in the Diabetic Neuropathy Drugs Market have been analyzed. Opportunities leading to market growth have been analyzed and stated. The report focuses on the global market and provides answers to the most important questions that stakeholders are facing today in the world. Information on the size of the market raises the issue of expanding competitiveness and hindering market-leading sectors and market growth.

The report provides an overview of the Diabetic Neuropathy Drugs market in several key countries spread across different geographic regions around the world. The report focuses on identifying various market trends, dynamics, growth drivers and factors restraining the market growth. Further, the report provides detailed insights into various growth opportunities and challenges based on various types of products, applications, end users and countries, among others. The global Diabetic Neuropathy Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

Have a Need More Info Download PDF Brochure:https://www.healthcareintelligencemarkets.com/request_sample.php?id=141080

The Key manufacturers that are operating in the global Diabetic Neuropathy Drugs market are:Daiichi Sankyo Company, Limited Johnson & Johnson Services, Inc. Novartis AG Pfizer Inc. Eli Lilly and Company

Report Scope:

Report Overview:

This study was conducted with a global perspective in terms of the various segments in the Diabetic Neuropathy Drugs market. Market sizing and forecast have been conducted for 5 geographic regions: North America, Latin America, Europe, Middle East and Africa (MEA), and Asia-Pacific. All market sizing data is provided in US$ with historic data for the years 2018 and 2019, along with estimations and forecast for the period from 2020 to 2025.

The ongoing COVID-19 pandemic has had a significant impact on the overall international trade and businesses. This report provides the latest insights into the Diabetic Neuropathy Drugs market factoring in various effects of the industry disruptions and halts caused by COVID-19.

Ask for Discount on the Report:https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=141080

Market Segmentation:Diabetic Neuropathy Drugs Market, by Type:

Diabetic Neuropathy Drugs Market, by Application:

Diabetic Neuropathy Drugs Market, by Geography:

Benefits of Buying Reports:

Table of Contents:

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Part 07:Five Forces Analysis

Part 08:Market Segmentation

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Part 16:Appendix

Note: If you have any special requirement, please let us know and we will offer you the report as you want.

About Us:

HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries. Being a B2B firm, we help businesses to meet the challenges of an ever-evolving market with unbridled confidence. We craft customized and syndicated market research reports that help market players to build game-changing strategies. Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare IT industries. Our intelligence enables our clients to make decisions with which in turn proves a game-changer for them. We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.

Contact Us:

HealthCare Intelligence MarketsAddress: 90, State Office Center,90, State Street Suite 700,Albany, NY 12207Email:sales@healthcareintelligencemarkets.comWebsite:www.healthcareintelligencemarkets.comPhone:+1 (888) 616-2766

Originally posted here:
Diabetic Neuropathy Drugs Market Key Drivers, Applications, Challenges and Opportunities, 2021-2028 - The Courier

Read More...

Market Assessment of Diabetic Neuropathy Industry including Top Players like Pfizer, Janssen Pharmaceuticals, Eli Lilly and Company, ACTAVIS,…

Wednesday, March 3rd, 2021

The latest survey on the Global Diabetic Neuropathy Market is conducted covering various organizations of the industry from different geographies to come up with a 100+ page report. The study is a perfect mix of qualitative and quantitative information highlighting key market developments, challenges that industry and competition are facing along with gap analysis and new opportunity available and trend in the Diabetic Neuropathy Market.

Initially, the report provides a basic overview of the industry including definitions, classifications, applications, and industry chain structure. The Diabetic Neuropathy market analysis is provided for the international markets including development trends, competitive landscape analysis by leading company profiles like Pfizer, Janssen Pharmaceuticals, Eli Lilly and Company, ACTAVIS, Cephalon, MEDA Pharma & Co. KG, etc., and key regions development status.

To Get a Copy of the Sample Report Kindly Connect with us https://www.affluencemarketreports.com/industry-analysis/request-sample/1130063/

This report looks at the current economic impact of COVID-19. This outbreak fundamentally changed the global economic situation. The current scenario of an ever-evolving corporate sector, as well as current and future impact assessments, are also discussed in the report.

Major highlights of Diabetic Neuropathy market report:

The Top Players Profiled in Diabetic Neuropathy Research study are:

Global Diabetic Neuropathy Market: Product Type Segment Analysis

Global Diabetic Neuropathy Market: Application Segment Analysis

Global Diabetic Neuropathy Market: Regional Segment Analysis

The Diabetic Neuropathy industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered.

ENQUIRE MORE ABOUT THIS REPORT @ https://www.affluencemarketreports.com/industry-analysis/request-inquiry/1130063/

CHAPTERS COVERED IN THIS REPORT ARE AS FOLLOW:

Chapter 1: Diabetic Neuropathy Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2: Diabetic Neuropathy Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3: Value Analysis, Production, Growth Rate, and Price Analysis by Type of Diabetic Neuropathy.

Chapter 4: Downstream Characteristics, Consumption, and Market Share by Application of Diabetic Neuropathy.

Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Diabetic Neuropathy by Regions (2014-2020).

Chapter 6: Diabetic Neuropathy Production, Consumption, Export and Import by Regions (2014-2020).

Chapter 7: Diabetic Neuropathy Market Status and SWOT Analysis by Regions.

Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Diabetic Neuropathy.

Chapter 9: Diabetic Neuropathy Market Analysis and Forecast by Type and Application (2020-2026).

Chapter 10: Market Analysis and Forecast by Regions (2020-2026).

Chapter 11: Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12: Market Conclusion of the Whole Report.

Chapter 13: Appendix Such as Methodology and Data Resources of This Research.

For More Details on Impact of COVID-19 on Diabetic Neuropathy Market https://www.affluencemarketreports.com/industry-analysis/covid19-request/1130063/

Research Objective Diabetic Neuropathy Market Research:

The report is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers and partners, end-users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Get Extra Discount on Diabetic Neuropathy Market Report, If your Company is Listed in Above Key Players List @ https://www.affluencemarketreports.com/industry-analysis/request-discount/1130063/

About Affluence:

Affluence Market Reports is the next generation of all your research needs with a strong grapple on the worldwide market for industries, organizations, and governments. Our aim is to deliver exemplary reports that meet the definite needs of clients, which offers an adequate business technique, planning, and competitive landscape for new and existing industries that will develop your business needs.

We provide a premium in-depth statistical approach, a 360-degree market view that includes detailed segmentation, key trends, strategic recommendations, growth figures, Cost Analysis, new progress, evolving technologies, and forecasts by authentic agencies.

For More Details Contact Us:

Affluence Market Reports

Contact Person: Mr. Rohit

Phone Number:

U.S: +1-(424) 256-1722

U.K.: +44 1158 88 1333

Email: [emailprotected]

Website: http://www.affluencemarketreports.com

Read the original:
Market Assessment of Diabetic Neuropathy Industry including Top Players like Pfizer, Janssen Pharmaceuticals, Eli Lilly and Company, ACTAVIS,...

Read More...

The News Journal Baptist Health Wound Care offers help with winter wounds – The News Journal

Wednesday, March 3rd, 2021

With severe winter weather upon us, outdoor activities can result in wounds for an unfortunate few.

Precipitation, such as snow, sleet and freezing rain, can make sidewalks and parking lots dangerous. Falls are much more prevalent during these weather conditions and can result in skin tears and painful abrasions. Sitting close to fireplaces, space heaters or other heat sources can cause burns on the extremities. Many diabetics experience neuropathy keeping these burns from even being noticed, leading to an increased risk of infection.

Megan Barton, APRN, of the Wound Care Center cautions, One of the most common, but often underestimated conditions during this winter season is frostbite.

Frostbite occurs when your skin freezes during exposure to cold weather or water, causing either visible or invisible damage to your cells and soft tissues. Frostbite usually affects your extremities (fingers, toes and ears) first, but can also affect your cheeks, chin or any other exposed skin.

Too much time outdoors in the cold, particularly for those with diabetic neuropathy, can lead to frostbite. Symptoms can include numbness, swelling, blisters, redness or blackened skin.

If you have exposed skin during extremely cold temperatures, you are at risk of developing frostbite. You also are at a higher risk if you take medicine for high blood pressure, have diabetes, suffer from poor circulation, or have been drinking alcohol or taking drugs.

Timely diagnosis and treatment from experts is essential to maximize tissue salvage and achieve the best results, stresses Barton.

Winter weather can be fun for some, tedious for others, but can be dangerous for all. Dress appropriately. Be extremely aware of your extremities, if you have neuropathy. Limit your exposure to the bitter temperatures, and if you are concerned about a wound or frostbite injury, you can call Baptist Health Wound Care at (606) 526-4565 or visit BaptistHealthCorbin.com/wound. Physician referral not required.

Originally posted here:
The News Journal Baptist Health Wound Care offers help with winter wounds - The News Journal

Read More...

Impact of COVID-19 on Neuropathy Pain Treatment Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | Pfizer, Depomed, Eli Lilly,…

Wednesday, March 3rd, 2021

Neuropathy Pain Treatment Market research report is the new statistical data source added by A2Z Market Research.

Neuropathy Pain Treatment Market is growing at a High CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Neuropathy Pain Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=170645

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals.

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Neuropathy Pain Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Neuropathy Pain Treatment markets trajectory between forecast periods.Regions Covered in the Global Neuropathy Pain Treatment Market Report 2021: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=170645

Regions Covered in the Global Neuropathy Pain Treatment Market Report 2021: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global Neuropathy Pain Treatment Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Neuropathy Pain Treatment market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Neuropathy Pain Treatment market.

Table of Contents

Global Neuropathy Pain Treatment Market Research Report 2021 2027

Chapter 1 Neuropathy Pain Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Neuropathy Pain Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=170645

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

More here:
Impact of COVID-19 on Neuropathy Pain Treatment Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | Pfizer, Depomed, Eli Lilly,...

Read More...

FDA Action Alert: Athenex, Blueprint, CorMedix and More – BioSpace

Wednesday, March 3rd, 2021

The end of February and beginning of March is a busy time for the U.S. Food and Drug Administration (FDA), with a number of PDUFA dates on the calendar. Read on for more.

Athenexs Oral Paclitaxel for Metastatic Breast Cancer

Athenexhas a target action date of February 28, 2021, for its New Drug Application (NDA) for Oral Paclitaxel for metastatic breast cancer, under Priority Review. The submission was built on topline data released in August 2019 for its Phase III trial.

On December 9, 2020, the company presented updated Phase III progression-free survival (PFS) and overall survival (OS) data on the clinical benefits in efficacy and tolerability of oral paclitaxel versus intravenous paclitaxel (IVP) in patients with metastatic breast cancer. The median PFS data demonstrated a benefit for oral paclitaxel compared to IVP, 8.4 versus 7.4 months, respectively, and median OS data was 23.2 months compared to 16.3 months, respectively.

The oral paclitaxel regimen appears to overcome some of the limitations of IV therapy, particularly in terms of reducing the risk of neuropathy, said Gerardo Antonio Umanzor Funez, lead investigator and medical oncologist at Centro Oncologico Integral, working with DEMEDICA of San Pedro Sula, Honduras. The lessened burden of neuropathy, the ability to manage GI side effects with prophylactic treatments, and the convenience of home-based administration, could be transformational in the treatment of metastatic breast cancer, especially in the current environment.

Blueprint Medicines Pralsetinib for Thyroid Cancer

Blueprint Medicines had a target action date of February 28 for its NDA for pralsetinib for patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. It was accepted for review under the agencys Real-Time Oncology Review (RTOR) pilot program. Its designed to assess a more efficient review process. It was approved on December 1, 2020, and will be marketed as Gavreto (pralsetinib).

The approval expanded the labeled indications for Gavreto to include adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, if radioactive iodine was appropriate.

Gavreto is a once-daily oral therapy that potently and selectively targets RET alterations that drive multiple tumor types. It is jointly commercialized in the U.S. by Blueprint and Genentech, a Roche company.

CorMedix Defencath for Bloodstream Infections Associated with Catheters in Hemodialysis Patients

CorMedix has a target action date of February 28 for its NDA for Defencath for the treatment of life-threatening bloodstream infections associated with the use of central venous catheters in patients receiving chronic hemodialysis. It has been designated by the FDA as a Fast Track and Qualified Infectious Disease Product, which offers an additional five years of marketing exclusivity.

On November 18, 2020, the company announced that the FDA had decided to cancel the Antimicrobial Drug Advisory Committee meeting that had been tentatively scheduled for January 14, 2021, to discuss the NDA.

Defencath is a proprietary formulation of taurolidine 1.35%, citrate 3.5% and heparin 1000 units/mL. Taurolidine is an amino acid derivative that has broad antimicrobial activity against gram-positive and -negative bacteria, including antibiotic resistant strains, in addition to mycobacteria and clinically relevant fungi including Aspergillus. The company also is working to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients.

Sanofis Libtayo for Advanced Non-Small Cell Lung Cancer

Sanofihad a target action date of February 28 under Priority Review of Libtayo (cemiplimab-rwlc) for advanced non-small cell lung cancer with 50% PD-L1 expression. Libtayo is a fully human monoclonal antibody that targets the PD-1 immune checkpoint receptor on T-cells. On February 22, 2021, the FDA approved Libtayo for this indication. The patients must either have metastatic or locally advanced tumors that are not candidates for surgery or definitive chemoradiation, and the tumors must not have EGFR, ALK or ROS1 aberrations. The PD-L1 expression level is determined by an FDA-approved test.

The approval of Libtayo to treat first-line advanced non-small cell lung cancer with high PD-L1 expression means physicians and patients have a potent new treatment option against this deadly disease, said Naiyer Rizvi, Price Family Professor of Medicine, Director of Thoracic Oncology and Co-director of Cancer Immunotherapy at Columbia University Irving Medical Center. Notably, Libtayo was approved based on a pivotal trial where most chemotherapy patients crossed over to Libtayo following disease progression, and that allowed for frequently underrepresented patients who had pretreated and clinically stable brain metastases, or who had locally advanced disease and were not candidates for definitive chemoradiation.

KemPharms KP415 for ADHD

KemPharmhas a target action date of March 2 for the NDA for KP415 for treatment of attention deficit hyperactivity disorder (ADHD). The drug is made up of serdexmethylphenidate (SDX), the companys prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH. It is designed to address unmet needs with the most widely-prescribed methylphenidate ADHD treatments, including earlier onset of action, longer duration of therapy, and avoiding unnecessary spikes in d-MPH concentrations.

On December 2, 2020, after a Late-Cycle Communication Meeting with the FDA, company president and chief executive officer Travis Mickle stated, The late-cycle review meeting with the FDA continued a series of productive meetings with the agency, and sets the stage for the next phase of the NDA review process, including the potential for confidential discussions of the KP415 product label.

Gilead and Kites Yescarta for R/R Follicular Lymphoma and Marginal Zone Lymphoma

Gilead Sciencesand Kite Pharma, a Gilead company, have a target action date of March 5 for their Yescarta (axicabtagene ciloleucel) for the treatment of follicular lymphoma (FL) and marginal zone lymphoma (MZL). The results from the ZUMA-5 clinical trial was the basis for the supplemental Biologics License Application (sBLA).

On December 5, 2020, the companies announced results from the primary analysis of ZUMA-5, a Phase II trial of Yescarta in adults with r/r indolent non-Hodgkin lymphoma (iNHL) after at least two previous lines of therapy. In the trial 92% of iNHL patients responded, including 76% with a complete response (CR) at a median follow-up of 17.5 months. The drug had previously been granted a Breakthrough Therapy Designation (BTD) by the FDA for FL and MZL.

It is encouraging to see this level of response to CAR T-cell therapy in a heavily pretreated and multiply relapsed patient population, in whom response duration to other available therapies is expected to be short, said Caron A. Jacobson, medical director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute and Assistant Professor of Medicine, Harvard Medical School.

Most Read Today

More:
FDA Action Alert: Athenex, Blueprint, CorMedix and More - BioSpace

Read More...

BR Retains its Role in Frontline Waldenstrm Macroglobulinemia Despite the Utility of BTK Inhibitors – OncLive

Wednesday, March 3rd, 2021

The treatment landscape of Waldenstrm macroglobulinemia (WM) is becoming increasingly complex with second-generation BTK inhibitors; however, the combination of bendamustine and rituximab (Rituxan; BR) remains the frontline standard of care for this patient population, said Morie A. Gertz, MD, in a virtual presentation during the 25th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma, an event hosted by Physicians Education Resource, LCC.

BR remains the frontline standard of care for patients with WM based on data from a phase 3 trial (NCT00991211) showing improved progression-free survival (PFS), less toxicity, and fewer relapses with BR vs R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone] in patients with WM (n = 41), said Gertz, a consultant in the Division of Hematology, Department of Internal Medicine, and a professor of medicine at Mayo Clinic.1

To build upon this regimen, rituximab was evaluated as maintenance therapy in the phase 3 StiL NHL-2008 MAINTAIN trial. The study randomized 218 patients who responded to BR induction therapy to rituximab maintenance or observation. The 2-year course of rituximab maintenance led to a numerical improvement in PFS of 101 months compared with 83 months with observation in this patient population; however, the difference in PFS was not statistically significant (HR, 0.80; 95% CI, 0.51-1.25; P = .32).2 As such, rituximab maintenance is not indicated for patients with WM who respond to BR induction, said Gertz.

Other treatment options for patients with WM include bortezomib (Velcade) in combination with dexamethasone and rituximab. This regimen induced an overall response rate (ORR) of 96% in patients (n = 23) and a median time to response (TTR) of 1.4 months.3

Similarly, carfilzomib (Kyprolis) plus rituximab and dexamethasone led to an ORR of 87.1% in patients (n = 31) and a median TTR of 2.1 months.4 Moreover, responses were not affected by MYD or CXCR4 mutational status, and the combination did not cause higher than grade 1 peripheral neuropathy, explained Gertz.

Carfilzomib is less neurotoxic than bortezomib, Gertz said. Neurotoxicity is a real issue in patients with IgM monoclonal proteins [because] they have high peripheral neuropathy rates with bortezomib.

In addition to these therapies, BTK inhibitors have led to a paradigm shift in WM, said Gertz.

In 2015, ibrutinib (Imbruvica) was granted a breakthrough therapy designation by the FDA as monotherapy for the treatment of patients with WM.5 Updated results of the pivotal study that led to the approval reported an ORR of 90.5% and a major response rate of 79.4% at a median follow-up of 59 months.6 Improvement in immunoglobulin M serum (IgM), bone marrow disease involvement, and hemoglobin were also observed.

Grade 3 or greater adverse effects (AEs) included neutropenia (15.9%), thrombocytopenia (11.1%), and pneumonia (3.2%). Notably, a 12.7% rate of atrial arrhythmia was observed with ibrutinib.

Atrial fibrillation in this elderly population raises issues of anticoagulation, rate control, and ablation. It is a serious complication in this group, said Gertz.

In 2018, the FDA expanded the label for ibrutinib to include its use in combination with rituximab to treat patients with WM based on findings from the phase 3 iNNOVATE trial.7

In December 2020, the prescribing information for ibrutinib was updated to include efficacy and safety data from the final analysis of the iNNOVATE trial, which demonstrated significantly higher rates of PFS with ibrutinib/rituximab (n = 75) compared with placebo/rituximab (n = 75) in patients with treatment-nave and relapsed/refractory disease.8

At Mayo Clinic, we still use BR as our first-line [regimen], with the exception of central nervous system lymphoplasmacytic lymphoma, or so-called Bing-Neel Syndrome. In this situation, bendamustine does not cross the blood-brain barrier, but ibrutinib does, said Gertz.

Additionally, the second-generation BTK inhibitor acalabrutinib (Calquence) was evaluated in a phase 2 trial in patients with treatment-nave (n = 14) or relapsed/refractory (n = 92) WM.9 Findings from the study demonstrated an ORR of 93% in both cohorts of patients. Moreover, a lower rate of severe atrial fibrillation was observed with acalabrutinib (1%) compared with what had been reported with ibrutinib.

Another second-generation BTK inhibitor, zanubrutinib (Brukinsa) was compared with ibrutinib in the ASPEN trial, wherein the rate of complete response plus very good partial response was 28.4% with zanubrutinib compared with 19.2% with ibrutinib (P = .09).10 Notably, the 12-month PFS and 12-month overall survival rates in the overall and relapsed/refractory populations were numerically improved with zanubrutinib vs ibrutinib.

Additionally, regarding safety, zanubrutinib was associated with lower rates of atrial fibrillation, contusion, diarrhea, peripheral edema, hemorrhage, muscle spasms, pneumonia, and AEs leading to treatment discontinuation or death compared with ibrutinib.

Although the efficacy improvements in the ASPEN trial were not considered statistically significant, the lower rates of toxicity suggest that zanubrutinib could have clinical utility for patients with WM, said Gertz.

Taken collectively, these data provide a potential treatment algorithm for patients with WM. At Mayo Clinic, current practice dictates that patients with IgM monoclonal gammopathy of undetermined significance with less than 10% lymphoplasmacytic infiltration, asymptomatic/smoldering WM, and patients with no cytopenias can be safely observed without therapeutic intervention. Single-agent rituximab should be given to those with IgM-related neuropathy, WM-associated hemolytic anemia, or symptomatic cryoglobulinemia. Finally, 4 to 6 cycles of BR without rituximab maintenance should be given to those patients with bulky disease, profound cytopenias, constitutional symptoms, and/or hyperviscosity symptoms, Gertz said.

Patients who had a response to previous therapy lasting 3 or more years could be considered for retreatment with their original therapy. Conversely, patients whose response was less than 3 years should be considered for zanubrutinib, acalabrutinib, or ibrutinib monotherapy if not previously used, bortezomib plus dexamethasone and rituximab if preexisting peripheral neuropathy is less than grade 2, rituximab plus dexamethasone and cyclophosphamide, or BR alone if not previously used.

Original post:
BR Retains its Role in Frontline Waldenstrm Macroglobulinemia Despite the Utility of BTK Inhibitors - OncLive

Read More...

Daratumumab Monotherapy Safe in Heavily Treated Relapsed or Refractory Multiple Myeloma – DocWire News

Wednesday, March 3rd, 2021

An early access treatment protocol (EAP) found that daratumumab monotherapy was safe in a population of patients with heavily treated relapsed or refractory multiple myeloma (RRMM).

Collectively, this EAP provides additional evidence of the favorable safety profile of daratumumab in patients with heavily pre-treated RRMM and the associated maintenance of patient-reported health-related quality of life (HRQoL), the researchers concluded.

Patients who were previously treated with at least three lines of therapy including a including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) or who were double refractory to a PI and IMiD were given intravenous daratumumab 16 mg/kg.

Final analysis included 293 patients who received at least one dose of daratumumab. A third of patients were from the UK, a quarter each from Spain and Italy, and 17.1% from Russia. The median age was 64 years (range, 32-85 years); 13.7% of patients were aged 75 years or older. Most patients were male (56.7%), White (93.5%), and had a baseline Eastern Cooperative Oncology Group performance status of 0 or 1 (88.7%).

Patient histories included vascular disorders (38.9%); surgical and medical procedures (31.1%); musculoskeletal and connective tissue disorders (22.9%); metabolism and nutrition disorders (20.8%); and benign, malignant, and unspecified (including cysts and polyps) neoplasms (15.0%). Comorbidities affecting more than 5% of patients included hypertension (31.4%), peripheral neuropathy (6.8%), anemia (6.8%), hypercholesterolemia (5.8%), deep vein thrombosis (5.5%), back pain (5.5%), and pulmonary embolism (5.1%).

The median duration of daratumumab exposure was 4.2 months (range, 0.03-24.1 months), and median number of infusions was 13 (range, 1-37). The overall response rate was 33.1%. Progression-free survival was 4.63 months. Overall, 60.1% of patients experienced grade 3 or 4 treatment-emergent adverse events (AEs), the most common being thrombocytopenia (18.8%), anemia (11.9%), and neutropenia (11.6%); serious AEs most commonly reported were pneumonia (4.4%) and pyrexia (4.1%).

Overall, the study yielded no new safety signals, and patients maintained their HRQoL, the study authors reported.

The study was published in Oncology and Therapy.

View original post here:
Daratumumab Monotherapy Safe in Heavily Treated Relapsed or Refractory Multiple Myeloma - DocWire News

Read More...

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Industry Perspective, Comprehensive Analysis, and Forecast 2028||Nemus Bioscience,…

Sunday, February 14th, 2021

Global chemotherapy induced peripheral neuropathy treatment marketis expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market.

The analysis covered in the Chemotherapy Induced Peripheral Neuropathy Treatment marketing report gives an assessment of various segments that are relied upon to witness the quickest development amid the approximated forecast frame. The numerical and statistical data has been denoted in the graphical format for a clear understanding of facts and figures. This market report contains historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. It not only identifies the emerging trends along with major drivers, challenges and opportunities in the market but also analyses them efficiently.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-chemotherapy-induced-peripheral-neuropathy-treatment-market

The major players covered in the chemotherapy induced peripheral neuropathy treatment market are Metys Pharmaceuticals, Nemus Bioscience, Sun Pharmaceutical Industries Pvt Ltd., PledPharma, Mylan N.V., GlaxoSmithKline, plc., Regenacy Pharmaceuticals, Pfizer, Inc., Asahi Kasei Pharma, Apexian Pharma, Solasia Pharma, Immune Pharmaceuticals, DermaXon, Krenitsky Pharmaceuticals among other domestic and global players.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Scope and Market Size

The chemotherapy induced peripheral neuropathy treatment market is segmented on the basis of treatment, drug class, drug type, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Enquire Here Get customization & check discount for report @:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-chemotherapy-induced-peripheral-neuropathy-treatment-market

Chemotherapy Induced Peripheral Neuropathy Treatment Market Country Level Analysis

The chemotherapy induced peripheral neuropathy treatment market is analysed and market size information is provided by country, treatment, drug class, drug type, end-users and distribution channel as referenced above.

The countries covered in the chemotherapy induced peripheral neuropathy treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K.,Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to the presence of high healthcare expenditure and favourable reimbursement policies for the treatment. Europe accounts the second largest market share due to increased genetic disorders and presence of refined medical facilities. Asia-Pacific is expected to account for the largest market share over coming years for the chemotherapy induced peripheral neuropathy treatment market due to constant rise in the incidence of cancer with increased demand for cost-efficient therapeutics.

Table of Contents:

Request for Detailed TOC:https://www.databridgemarketresearch.com/toc/?dbmr=global-chemotherapy-induced-peripheral-neuropathy-treatment-market

Opportunities in the market

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Corporatesales@databridgemarketresearch.com

Here is the original post:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Industry Perspective, Comprehensive Analysis, and Forecast 2028||Nemus Bioscience,...

Read More...

Microalbuminuria Is Higher in Patients With Uncontrolled Diabetes – MD Magazine

Sunday, February 14th, 2021

Urine spot for albumin:creatinine ratio (UACR) values are higher in patients with uncontrolled type 2 diabetes (T2D) and in patients with a longer duration of disease, according to new research.

The findings bolster the case for annual UACR tests as a routine part of care, the authors concluded, since the tests can identify early signs of diabetic nephropathy.

Diabetic nephropathy is a complication of diabetes that is linked with chronic kidney disease leading to end-stage renal disease. Early detection of nephropathy can be a key factor in clinical outcomes. The presence of albumin in urine is associated with diabetic neuropathy. The American Diabetes Association recommends yearly screening for microalbuminuria. UACR is a more efficient method of testing for albumin, replacing the older standard of 24-hour urine collection.

Corresponding author Ayesha Malik, of Hameed Latif Hospital, in Pakistan, and colleagues noted that strict glycemic control can prevent microalbuminuria. The investigators sought to better understand how common microalbuminuria is among patients with T2D and the extent to which it correlates with diabetic control.

Malik and colleagues recruited 133 patients for their study, and recorded data such as body mass index, duration of diabetes, and hemoglobin A1C levels. The patients were given morning, mid-stream UACR tests, which were then evaluated for albumin.

The study population was mostly male (60.9%) and had an average age of 54.5 years. The mean duration of diabetes in the group was 6.29 years, and mean A1C was 8.99%.

Overall, 30.1% of patients had diabetic neuropathy, and 25.6% had microalbuminuria. In addition, 4.5% had macroalbuminuria.

The investigators then performed a Pearson product-moment correlation coefficient, which showed that high UACR correlated with a higher likelihood of uncontrolled diabetes and a longer duration of diabetes.

Some of the factors that influence kidney disease development include genetics, blood sugar control, and blood pressure, the authors said. The impact of strict diabetic control on prognosis is most pronounced in patients microalbuminuria. We found a significant correlation between higher HbA1c level and presence of microalbuminuria.

The investigators noted that T2D is growing in prevalence around the world, and they said local studies in the South Asian region have shown rates of microalbuminuria among patients with T2D that align with this new study.

However, due to poor healthcare infrastructure and lack of education, people are not routinely screened in developing or underdeveloped countries and end up presenting late in the disease course, they wrote.

Limitations of the study included the small sample size and the fact that the investigators did not take into account patients detailed drug histories or their histories of dietary protein intake prior to UACR. These factors could potentially alter UACR values.

Still, the investigators said their data show routine UACR testing can be an important component of kidney disease prevention.

Both early detection and progress of the disease can be determined by sensitive markers like the UACR, they concluded. In addition, our study shows that poorly controlled diabetes is associated with higher UACR. Involvement of the UACR in routine practice should be considered for all diabetic patients.

The study, "Prevalence of Microalbuminuria in Type 2 Diabetes Mellitus," was published online in Cureus.

Read more:
Microalbuminuria Is Higher in Patients With Uncontrolled Diabetes - MD Magazine

Read More...

Chemotherapy Induced Peripheral Neuropathy Treatment Market Size 2021 | Covid-19 Impact Analysis | Business Outlook, Growth, Trends and Forecasts 2027…

Sunday, February 14th, 2021

Fort Collins, Colorado: Chemotherapy Induced Peripheral Neuropathy Treatment Market Research is a precise analysis of the historical, current, and future phases of the market. The report was released specifically for business owners, executives, policymakers, and Chemotherapy Induced Peripheral Neuropathy Treatment stakeholders to determine likely market conditions. A few key aspects are highlighted in the Chemotherapy Induced Peripheral Neuropathy Treatment market report including raw materials, market strategies, production volumes, sales, and CAGR.

The report also sheds light on key market characteristics such as dynamics, viable market structure, global price volatility, supply and demand, market restraints, restraints, and growth drivers. The report also covers other important aspects like demand ratio, Chemotherapy Induced Peripheral Neuropathy Treatment price violations, strict rules, and unpredictable market fluctuations. It also highlights several growth drivers that may increase market returns in the near future.

Download Exclusive Sample Copy along with few company profiles @ https://reportsglobe.com/download-sample/?rid=103470

In-depth study of major segments of the Chemotherapy Induced Peripheral Neuropathy Treatment market:

The Chemotherapy Induced Peripheral Neuropathy Treatment market report also highlights the adverse effects of Covid-19 globally as well as at all levels of the Chemotherapy Induced Peripheral Neuropathy Treatment market and offers key projections for 2027. In addition to the impact of pandemic, the Chemotherapy Induced Peripheral Neuropathy Treatment market is growing. develops rapidly. CAGR stable over the past decade. The market is also expected to grow more strongly during the forecast period. The market keeps pace with active research and development, technological advancement and rapid industrialization.

Chemotherapy Induced Peripheral Neuropathy Treatment Market also provides key insights into market segments that help players develop sound business strategies and deliver accurate products and services to their customers. He also helps market players and Chemotherapy Induced Peripheral Neuropathy Treatment business owners identify their potential buyers and grow their existing customer base so that they can better serve their customers. It also allows readers to plan specific directions and stay ahead of their competition.

Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation, By Type

Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation, By Application

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=103470

Leading Companies on the Chemotherapy Induced Peripheral Neuropathy Treatment market:

The study also highlights the details and estimates of major manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment operating in the Chemotherapy Induced Peripheral Neuropathy Treatment market. It helps gamers to analyze how their competitors have performed in the market over the past few years and how they will perform in the near future. The report provides an important analysis of financial metrics, revenue patterns, sales volume, average annual expenses, profitability and CAGR, along with a study of their organizational, financial and productive details, business strategies, product launches and promotions., Quantities and production capacity.

Market Segments by Major Manufacturers:

Geographical scenario:

The geographical analysis of the Chemotherapy Induced Peripheral Neuropathy Treatment market has been done by examining different global regions such as North America, Latin America, Middle East, Asia-Pacific, and Africa on the basis of different parameters. The primary target for the Chemotherapy Induced Peripheral Neuropathy Treatment market is the Chemotherapy Induced Peripheral Neuropathy Treatment countries. The Chemotherapy Induced Peripheral Neuropathy Treatment market has broadly compiled through extensive research and analysis techniques such as qualitative and quantitative analysis. Furthermore, it offers a blend of SWOT and Porters five techniques to analyze the data of the global market. Moreover, this report offers a complete analysis of different business perspectives such as the ups and downs of the global market shares. To expand the market at the global level, it makes use of different techniques and sales methodologies for achieving the outcomes of the businesses.

Collectively, this research repository encapsulates data of Chemotherapy Induced Peripheral Neuropathy Treatment market to offer strategic decision-making abilities to various investors, business owners, decision-makers as well as policymakers.

View market snapshot before purchasing @ https://reportsglobe.com/product/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-insight-and-forecast/

Following major key questions are addressed through this global research report:

1. What will be the Chemotherapy Induced Peripheral Neuropathy Treatment market size over the forecast period?2. What are the demanding regions for making significant growth in the upcoming future?3. What are the challenges in front of the Chemotherapy Induced Peripheral Neuropathy Treatment market?4. Who are the key vendors in Chemotherapy Induced Peripheral Neuropathy Treatment market?5. What are the effective sales patterns and methodologies for boosting the performance of the Chemotherapy Induced Peripheral Neuropathy Treatment market?6. What are the different ways to find out potential customers as well as global clients?7. Which factors are hampering the Chemotherapy Induced Peripheral Neuropathy Treatment market?8. What are the outcomes of SWOT and porters five techniques?9. What are the demanding trends of the Chemotherapy Induced Peripheral Neuropathy Treatment market?

Key strategic developments in the Chemotherapy Induced Peripheral Neuropathy Treatment market:

This global study also includes the key strategic developments of the Chemotherapy Induced Peripheral Neuropathy Treatment market including the new product launchings, partnerships and collaboration among the key players functioning at the global level.

Request customization of the report @ https://reportsglobe.com/need-customization/?rid=103470

Key target audience for Chemotherapy Induced Peripheral Neuropathy Treatment report:

The report is insightful documentation and provides significant insights to customers, business owners, decision-makers, providers, distributors, suppliers, policymakers, manufacturers, investors, and individuals who have a keen interest in the Chemotherapy Induced Peripheral Neuropathy Treatment market.

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Website: Reportsglobe.com

Sarkari Results, Thrive Market Research

The rest is here:
Chemotherapy Induced Peripheral Neuropathy Treatment Market Size 2021 | Covid-19 Impact Analysis | Business Outlook, Growth, Trends and Forecasts 2027...

Read More...

Impact Of Covid-19 On Leber’s Hereditary Optic Neuropathy Drug Market 2020: Remarking Enormous Growth With Recent Trends | Alkeus Pharmaceuticals,…

Sunday, February 14th, 2021

Industry Growth Insights (IGI) recently published a report entitled, the Lebers Hereditary Optic Neuropathy Drug Market, describing the crucial aspects of the market by conducting an in-depth analysis of the current trend, emerging threats, and future market assessment. This report takes into account the adverse impact of the COVID-19 pandemic on the market for the period of 2020-2020 and provides a detailed information about how the market will perform during the forecast period, 2020-2027. Our research team presents the report in a simplistic manner supported by fact and actual figures that will assist clients to arrive an informed decision about their investment plans and business strategies.

Request Free Exclusive Sample on Lebers Hereditary Optic Neuropathy Drug Market Report @ https://industrygrowthinsights.com/request-sample/?reportId=198426

The report provides a holistic view of the market offering key insights of the market behavior over last four years and key assessment of the future market performance. It includes a systematic analysis of historical data for the period, 2015-2020 and draws upon assessment of the market performance for the forecast period, 2020-2027 by observing 2020 as the base year. With the reference to the available data, it provides vital insights on key factors such as drivers, restrains, trends, challenges, and opportunities of the Lebers Hereditary Optic Neuropathy Drug market growth.

This report provides a comprehensive outlook on the key segments and sub-segmentations that includes the complete information about the product types, applications, end-users and regions. It offers latest information regarding the growth rate, volume, and size of the market in respect to each segment and also explains the market performance of these segments in the respective five regions. Moreover, it discusses a wide range of the emerging market scope and potential drawbacks present in the segments.

Lebers Hereditary Optic Neuropathy Drug Market Report Includes:

The Global Lebers Hereditary Optic Neuropathy Drug Market Report is segmented into:

By Types:

ElamipretideGS-011IXC-201KH-176Others

By Applications:

HospitalClinicOthers

By Regions:

For More Information on This Report Visit: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=198426

The report covers the competitive landscape of various major global players, their current market positions, and key business strategies adopted to mark their major footprint in the market. This includes information about the product launch, expansion of the production facilities or plants, adoption of new technologies, latest merger & acquisition, partnership, and collaboration of the key players. It furthers provides concrete information about the existing market scope for the new entrants and the current competitive levels and scenario for the emerging players in the global market.

The Lebers Hereditary Optic Neuropathy Drug Market Report Covers the Following Companies:

Alkeus Pharmaceuticals, Inc.Biovista Inc.GenSight Biologics S.A.Ixchel Pharma, LLCKhondrion BVSpark Therapeutics, Inc.Stealth BioTherapeutics Inc.

Industry Growth Insights (IGI) also offers customized report for a particular product, application, and region as per the requirement of clients and provides additional companies profiles as per the clients request.

Regarding the methodology, the report is prepared by relying on primary and secondary sources including interviews of the company executives & representatives and accessing official documents, websites, and press release of the companies related to the Lebers Hereditary Optic Neuropathy Drug market. It also includes comments and suggestions from the experts in the market especially the representatives from government and public organizations as well as international NGOs. The report prepared by Industry Growth Insights (IGI) is known for its data accuracy and precise style, which relies on genuine information and reliable data source. Moreover, customized report can be available as per the clients wishes or specific needs. It takes into account of various research tools and methods including predictive analysis, Porters 5 force analysis, SWOT analysis, and real-time analytics.

You can buy the complete report: https://industrygrowthinsights.com/checkout/?reportId=198426

This report includes the estimation of market size in terms of value (USD) and volume (K MT), with applying top-down and bottom-up approaches to estimate and validate the overall scope of the market. The report is presented with a group of graphical representations, tables, and figures that shows a clear picture of the developments of the products and its market performance over the last few years. With this precise report, it can be easily understood the growth potential, revenue growth, product range, and pricing factors related to the Lebers Hereditary Optic Neuropathy Drug market. This report includes information on the latest government policies, norms, and regulations that can affect the dynamics of the market.

Why you should buy this report?

This report provides a complete guideline for the clients to arrive an informed business decision since it offers a comprehensive market outlook that will help the clients to understand better of the current & future market situation.

The report answers some of these key questions given below:

If you have any questions on this report, please reach out to us: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=198426

About Us:

Our reports are more than just research reports to us. They are tools that enable us to maintain long-term relationships with our clients whom we honor and cherish. Our clients business growth is integral for not only them but also us. This is what differentiates us from other market research companies.

At IGI, we provide our expertise and guideline for success. Our team of efficient and experienced researchers and consultants provide progressive market intelligence reports that are accurate, authentic, and in-depth. This empowers the clients to make well-informed decisions.

Moreover, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries including chemicals and materials, energy, automobile, healthcare, consumer goods, and technology. Our deep understanding of many business environments across industries such as those mentioned above allows us to deliver tailor-made reports.

Contact Us:

Alex MathewsHead of Business DevelopmentPhone No.: +1 909 545 6473Email [emailprotected] Website https://industrygrowthinsights.com Address 500 East E Street, Ontario, CA 91764, United States.

https://neighborwebsj.com/

Read more here:
Impact Of Covid-19 On Leber's Hereditary Optic Neuropathy Drug Market 2020: Remarking Enormous Growth With Recent Trends | Alkeus Pharmaceuticals,...

Read More...

What everyone should know about cancer and cold weather – Yahoo News

Sunday, February 14th, 2021

Cold weather can create health issues for many people, but some are more susceptible than others. In particular, cold can be especially difficult for cancer patients.

"Cancer, in general, puts a lot of stress on the body, and when we have stress on the body, we have trouble regulating other parts of our normal physiology," Dr. Nicholas Rohs, an oncologist at Mount Sinai in New York City, told AccuWeather.

Rohs said advising his patients about problems that can arise during cold weather is a regular part of his treatment routine.

It's not necessarily cancer itself that causes cold sensitivities -- it's therapies and side effects, Rohs said, that create problems, although cancer stresses out the entire system which puts a patient at a higher risk in general.

"People with really advanced cancers that are taking a really big toll on their body can have trouble regulating their own temperature," Rohs explained. "Inflammatory markers are flying around that can adjust how we are able to accommodate to our surroundings."

Chemotherapy and cold weather can be dangerous

Cold impacts can vary depending on the type of drug a patient is receiving. "Oxaliplatin is a very common chemotherapy medication we give," Rohs said. "That medication has a side effect called cold-induced neuropathy."

Patients being treated with Oxaliplatin who suffer cold-induced neuropathy can experience "numbness, tingling in their fingers, toes and even other parts of their bodies," Rohs said, adding that the condition "can get so bad they can be numb so they may not sense cold as well. But Oxaliplatin has this cold-induced neuropathy where when I give it to my patients they have hypersensitivity to cold to even a level where my patients say, 'I grabbed a sort of cold spoon and I couldn't hold it. I went to open my fridge and I couldn't.' And if it's really bad, people can be in an air-conditioned room and feel super uncomfortable because of it."

Story continues

Neuropathy is when the nerves malfunction, causing numbness or weakness. These patients experience cold temperatures, which can cause numbness, tingling, pain and muscle weakness. Neuropathies frequently start in the hands and feet but can affect other parts of the body as well. Rohs says this can cause them to be more prone to frostbite because they might not realize how cold their hands and fingers are getting in cold weather.

"If you have bad neuropathies -- and I actually have neuropathies not related to chemotherapy in my feet, I could go walk around in the snow for five or 10 minutes and not feel it the same way that a normal person would -- that can be really dangerous. If you can't sense the danger, you can't get away from it, so for people who have really significant neuropathies, they definitely need to be really thoughtful about wearing good cold-weather gear."

Rohs advises his patients to wear gloves and layers, so they can adjust to temperatures as they go in and out of buildings and different settings.

Julene Diedrich, a Marshfield Clinic nurse practitioner in Oncology tells Shine365, "We even tell these patients to avoid cold drinks or ice."

Cancer patients at higher risk of flu, cold, pneumonia and other viruses and infections

Chemotherapy can also compromise the immune system, making a patient extremely vulnerable to viruses or infections, which means common illnesses like the cold, flu or pneumonia can be life-threatening.

Rohs said someone who is not receiving chemotherapy might "easily fend off" a case of the common cold or flu, but "somebody who has a low blood count [a side effect of chemotherapy] might not be able to do the same. Patients receiving chemotherapy can also be susceptible to bacterial infection," he said. "They can get really robust pneumonia and things like that that they can't easily fight off."

One of the most common side effects of chemotherapy is that it attacks quickly dividing blood cells. Those cells include white and red blood cells. After a chemo treatment, patients often have lower white blood cell counts, particularly neutrophils, which are the first cells to arrive on the scene when someone experiences a bacterial infection. That's what lowers a patient's immunity. Having low red blood cell counts can make people feel colder and be more susceptible to cold.

"You don't have those red blood cells to circulate everything that you need and your body. If it's more anemic, your blood vessels in your peripheral part of your body -- the outsides of your body -- will clamp down more, so you can have more blood in your central areas because those are clearly more critical to us," Rohs said. "Our lungs, our heart -- all of these things are in the middle of our body."

So if the body is going into a state in which it's really cold, the circulatory system is going to shunt blood to the middle of our body, Rohs continued. "So when we're anemic, our body will try and keep most of the blood pool where it's most critical so you're likely to have cold fingers, toes, things like that."

Some patients can also be prone to cold-induced asthma, which occurs when lungs react to the temperature by narrowing, making it tougher to breathe.

"Patients who already have breathing issues, going out into the cold can be particularly irritating to their lungs and cause them to feel like their more short of breath and actually make them more short of breath because they can't breathe as well," Rohs said.

Cancer patients more prone to serious injury from an icy fall

In addition to treatment-induced issues, cancer patients often lose large amounts of weight, Rohs told AccuWeather. "Things like 20, 30 pounds for months so that's our biggest insulator," he said, adding that bodies that have lost a lot of weight due to chemotherapy can "have a lot of trouble regulating temperature."

Weight isn't just an insulator; it's padding that protects bones at a time when they are at their most fragile. Many cancer treatments cause bone loss also. Hormonal therapies often used to treat breast cancer can strip bone density, which is called osteoporosis. Osteopenia occurs when the body doesn't make new bone as quickly as it reabsorbs old bone. Both conditions put cancer patients at a high risk of becoming seriously injured when slipping and falling on ice. Rohs says a bone fracture can be devastating for a cancer patient whose body is already under tremendous stress.

"People have trouble adjusting to such an abrupt change in their physical health so they'll say, 'Well, I can still walk out to the street. Oh, it's a little icy, I do that all the time,' and they're more likely to fall and also when we talk about those neuropathies ...You might not be able to feel as steady on your feet, so you're more likely to slip and fall."

He added,"[If] we're having a snowstorm in New York I say. 'Hey -- stay home!' It's not the end of the world for many of my patients."

Bottom line, if you or someone you know is undergoing chemotherapy or other cancer treatments, pay particular attention to the weather forecast, so you can dress appropriately for the temperature.

"I tell my patients, you know, wear gloves, bring layers so that you can adjust to temperatures as you go in and out of buildings, or just different settings."

Keep checking back on AccuWeather.com and stay tuned to the AccuWeather Network on DirecTV, Frontier, Spectrum, Fubo, and Verizon Fios.

Read more from the original source:
What everyone should know about cancer and cold weather - Yahoo News

Read More...

FHN Health Column: Be careful in the cold protect your skin from frostbite – Freeport Journal-Standard

Sunday, February 14th, 2021

Journal Standard

Cold enough for you? This typical Midwest winter greeting pretty much sums up this weeks weather, but it should serve as a reminder, too it can be too cold.

As the temperature plunges and cold winds blow, so does the risk of frostbite. Skin exposed to extreme cold can develop frostbite in as little as five minutes, said FHN Podiatrist Roland Tolliver. Fingers in gloves and toes in boots can develop frostbite, too.

Though frostbite can happen to anyone, some conditions can make a person more susceptible: if you have diabetes, take blood thinners or smoke, your circulatory system may not work as efficiently or you may suffer from neuropathy, which means you have lost some feeling in your extremities. Poor circulation and neuropathy put you at higher risk for developing frostbite.

Skin that is cold and wet, like fingers in damp gloves and toes in wet socks, is even more susceptible to frostbite.

Danger Signs

Dr. Tolliver said one of the first signs of frostbite can be skin that is itchy, burnsor is numb. The skin also may turn white or greyish yellow, and as more damage occurs, feel waxy or hard. At its most severe, frostbite can cause blistering and even gangrene.

If you notice any of the signs of frostbite, go inside or get warmed up as quickly as possible.

Once you are in where its warm, remove any wet clothing and look closely at the affected area. You might see red skin and feel some pain or numbness. As you warm up, you may notice the area feels tingly that means the circulation is returning.

You can help speed the warming process by soaking the affected area in lukewarm not hot water. (The water temperature should be between 105-110 F.) Soak the area until the skin is back to its normal color and you dont feel any numbness.

A warm beverage like tea or cocoa can help you feel warmed up, too, but avoid any alcoholic beverages while your body is recovering from the cold. If you are feeling pain, an over-the-counter pain reliever may help.

If your pain increases or your skin doesnt return to its normal color, bundle up (in dry clothes leave the soggy gloves and boots behind) and head for the emergency department for medical attention.

Warm and dry

If youre planning to spend a lot of time outside in the cold, you probably know to wear long underwear and a turtleneck to help keep you warm.

Well-planned layers can help prevent frostbite, too: wear a thin pair of socks to pull moisture away from your feet underneath a thicker pair of socks for warmth. If you know youll be handling wet snow, wear waterproof gloves or layer pairs to keep your fingers as dry as possible.

Hand warmers and other gadgets to tuck in your pockets or shoes are easy to find this time of year, but people with poor circulation or who have lost some feeling in their extremities should be cautious using these items: if you cant feel your fingers or toes getting too cold, you likely wont be able to tell if they get too warm, either, and that can cause tissue damage, too.

The key to staying safe from frostbite, Tolliver said, is just to be aware of any signals your body may be sending. Take a warm-up break from shoveling or sledding when you need one with these temperatures, the snow isnt going anywhere!

Roland Tolliver, DPM, FACFAS, is a podiatrist at FHN. Hear more of his Dial-a-Doc interview on this topic at http://www.fhn.org/newsradio.asp.

Read more here:
FHN Health Column: Be careful in the cold protect your skin from frostbite - Freeport Journal-Standard

Read More...

VM202 Is Safe and Effective for Painful Diabetic Peripheral Neuropathy – Clinical Pain Advisor

Thursday, February 11th, 2021

VM202, a plasmid DNA that expresses 2 isoforms of hepatocyte growth factor, is both safe and effective in providing long-lasting pain relief in painful diabetic peripheral neuropathy (DPN), according to results of a phase 3-1b study published in Clinical and Translational Science.

Following positive efficacy and safety data results from phase 1 and 2 studies, researchers conducted a large scale, double-blind, placebo-controlled phase 2 study of VM202 for painful DPN. The study was conducted in 2 parts: the main study took place over 9 months (DPN 3-1; ClinicalTrials.gov identifier NCT02427464; N=500 participants), followed by a noninterventional 3-month safety and efficacy extension that included a subset of later-enrolling main study participants (DPN 3-1b; ClinicalTrials.gov identifier NCT04055090; n=101).

Researchers hypothesized that VM202 administration would reduce the average daily diabetic peripheral neuropathy pain scores more than placebo. The primary efficacy endpoint was the mean 24-hour numerical rating scale pain score, recorded in a daily pain and sleep diary at 3 months.

In both studies, most participants were White (74.4% and 80.2%) with an overall mean age of 61.5 years. Many participants had comorbid conditions, including hypertension, dyslipidemia, and obesity.

Between-group demographic and baseline characteristics were similar. At the time of randomization, roughly half of the participants were not receiving either pregabalin or gabapentin to manage DPN.

Researchers assessed safety based on incidence of treatment-emergent adverse events, serious adverse events, and adverse events of special interest (injection site reactions, ophthalmologic or acute cardiac events, foot ulcers, and symptoms of central nervous system depression).

In DPN 3-1, 72.6% of those treated with VM202 and 68.9% of those treated with placebo reported at least 1 treatment-emergent adverse event. The most common adverse events were infections and infestations, which were similar between groups.

Adverse events of special interest occurred in 17.2% and 16.8% of VM202 and placebo patients, respectively. The most common adverse events were diabetic retinopathy, peripheral edema, and skin ulcers. The incidence of these events that were deemed related to the study drug was low, with no difference between groups.

Serious adverse events were reported in 9.6% of the VM202 group and 9.9% of the placebo group. In the VM202 group, adenocarcinoma and vitreous hemorrhage were deemed possibly related to the study drug. Three myocardial infarctions were deemed not related to the study drug due to patients medical history.

In DPN 3-1b, 15.4% and 22.2% of VM202- and placebo-treated patients, respectively, experienced treatment-emergent adverse events. Adverse events of special interest were experienced by 3.1% and 2.8% of VM202- and placebo-treated patients, and included peripheral edema, chest pain, and angina pectoris. One participant in the VM202 group and 2 in the placebo group reported serious adverse events, but all 3 of these participants had relevant medical histories.

DPN 3-1 failed to meet the primary endpoints, with between-group differences that were not statistically significant for any endpoint measure. When the participants who were not receiving concurrent gabapentinoids were analyzed separately (n=251), endpoints remained statistically nonsignificant compared with placebo.

In DPN 3-1b, efficacy data differed strikingly, despite similar participant demographic and baseline characteristics. Although there was no significant pain severity difference at baseline, there were significant reductions in the primary efficacy endpoints at 12 months in the VM202 group compared with placebo. Significant pain reductions were also noted at 6 and 9 months, and greater pain reductions were identified in patients who were not taking gabapentin or pregabalin during the 12-month study, which was consistent with Phase 2 study results.

The researchers stated, To our knowledge, this is the first Phase 3 gene therapy study for pain that has ever been done. VM202 did not meet efficacy endpoints in the fullpopulation, but VM202 demonstrated long-term, clinically significant reductions in pain in [DPN 3-1b], particularly in [participants] not on gabapentinoids

They concluded, Given the excellent safety profile of VM202, the potential for disease modifying effects, and the high unmet medical needs of the DPN patient population not on gabapentinoids, further study is warranted.

Disclosure: This clinical trial was supported by Helixmith Inc. Please see the original reference for a full list of authors disclosures.

Kessler JA, Shaibani A, Sang CN, et al; for the VM202 Study Group. Gene therapy for diabetic peripheral neuropathy: a randomized, placebo-controlled phase 3 study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Published online January 19, 2021. Clin Transl Sci. doi:10.1111/cts.12977

Read the original here:
VM202 Is Safe and Effective for Painful Diabetic Peripheral Neuropathy - Clinical Pain Advisor

Read More...

Ischemic Optic Neuropathy Treatment Market is Driven by Increased Use of Intravitreal Implants for Treating Ophthalmology Diseases KSU | The Sentinel…

Thursday, February 11th, 2021

Global Ischemic Optic Neuropathy Treatment Market: Overview

Technological progress made in the treatment of ischemic optic neuropathy coupled with the availability of alternative drugs is expected to boost the growth of the global ischemic optic neuropathy treatment market over the period of analysis, from 2020 to 2030. Ischemic optic neuropathies (IONs) are one of the major reasons for seriously impaired vision or blindness usually amongst the elderly and middle-aged people. However, the disease can affect anyone and no human age is immune to it. Increased prevalence of the disease is anticipated to propel expansion of the global ischemic optic neuropathy treatment market in the years to come.

Ischemic optic neuropathies (IONs) come in two types, namely posterior ischemic optic neuropathy (PION) and anterior ischemic optic neuropathy (AION). Inflammation of the arteries that supply blood to the optic nerve causes anterior ischemic optic neuropathy and reasons other than inflammation cause non-anterior ischemic optic neuropathy. However, anterior ischemic optic neuropathy is more commonly found in people than posterior ischemic optic neuropathy. Immediate treatment is needed in case of anterior ischemic optic neuropathy to prevent loss of vision in the affected eye as it also causes damage in the other eye in a span of just 5 to 10 days.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78358

Hypercholesterolemia, diabetes, and hypertension are some of the causes of the disease. In addition, other medical conditions such as failure of autoregulation, severe anemia, vasospasm, nocturnal hypotension, sleep apnea, and hypoperfusion are likely to cause ischemic optic neuropathies.

Disease type, treatment type, end user, and region are the four important parameters based on which the global ischemic optic neuropathy treatment market has been classified. The thorough evaluation of the market comes with the objective of providing stakeholders with a detailed and clear analysis of the global ischemic optic neuropathy treatment market.

Global Ischemic Optic Neuropathy Treatment Market: Notable Developments

One of the significant developments that give a quick view of the dynamics pertaining to the global ischemic optic neuropathy treatment market is mentioned as below:

In July 2019, Pfizer Inc. acquired US-based pharmaceutical company, Array BioPharma Inc. This acquisition is estimated to strengthen innovative biopharmaceutical business and assist in the meeting the unmet medical needs of diseases like cancer and other rare diseases.

Request for Analysis of COVID-19 Impact on Ischemic Optic Neuropathy Treatment Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78358

Some of the prominent organizations in the global Ischemic optic neuropathy treatment market comprise the below-mentioned:

Global Ischemic Optic Neuropathy Treatment Market: Key Trends

The global ischemic optic neuropathy treatment market is characterized by the presence of the following restraints, drivers, and opportunities.

Increased Demand from Various End Use Sectors to Fuel Market Growth

The development of the global ischemic optic neuropathy treatment market is anticipated to register high growth rate over the tenure of assessment. The increased use of intravitreal implants for treating ophthalmology diseases is expected to open new avenues of growth for the global ischemic optic neuropathy treatment market over the forecast period, from 2020 to 2030. Many of the leading drug manufacturing and pharmaceutical companies from the developed countries are making high investment in the research and development activities so to develop better and advanced solutions and reduce the burden of vision and eye-related diseases. Increased spending in infrastructure and new, advanced technologies in ophthalmology therapeutics are likely to account for a larger share of the market in the years to come.

Pre Book Ischemic Optic Neuropathy Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=78358&ltype=S

For patients suffering from ischemic optic neuropathy, corticosteroid is considered as the first choice of therapy, particularly in countries like Russia, France, Germany, and the US. However, several patients have developed resistance to anti-VEGF, which is likely to boost growth of the global ischemic optic neuropathy treatment market over the period of analysis, from 2020 to 2030.

Global Ischemic Optic Neuropathy Treatment Market: Geographical Analysis

North America is estimated to exert dominance over the global ischemic optic neuropathy treatment market and the region is likely to retain its prominence throughout the period of analysis, from 2020 to 2030. Availability of advanced healthcare infrastructure together with increased spending on the research and development activities in the field of ophthalmology is expected to propel growth of the global ischemic optic neuropathy treatment market in the years to come.

More Trending Reports by Transparency Market Research

Digestive Enzymes Market: https://www.biospace.com/article/digestive-enzymes-market-growth-is-expected-to-occur-at-a-healthy-cagr-of-13-1-percent-from-2017-to-2025/

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

More:
Ischemic Optic Neuropathy Treatment Market is Driven by Increased Use of Intravitreal Implants for Treating Ophthalmology Diseases KSU | The Sentinel...

Read More...

Page 6«..5678..20..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick